US5273965A
(en)
*
|
1992-07-02 |
1993-12-28 |
Cambridge Biotech Corporation |
Methods for enhancing drug delivery with modified saponins
|
US5650398A
(en)
*
|
1992-07-02 |
1997-07-22 |
Cambridge Biotech Corporation |
Drug delivery enhancement via modified saponins
|
JP4129544B2
(en)
*
|
1993-03-29 |
2008-08-06 |
ファイザー・インク |
Multi-component clostridial vaccine using saponin adjuvant
|
FR2707646A1
(en)
*
|
1993-07-15 |
1995-01-20 |
Univ Toulouse |
Process for the extraction and purification of hemolytic saponins.
|
NL9301690A
(en)
*
|
1993-08-12 |
1995-04-18 |
Seed Capital Investments |
Compounds with adjuvant activity.
|
AU1077795A
(en)
*
|
1993-09-30 |
1995-04-18 |
Seed Capital Investments (Sci) B.V. |
Compounds with adjuvant activity
|
US5997873A
(en)
*
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
US5688772A
(en)
*
|
1994-08-01 |
1997-11-18 |
University Of Saskatchewan |
Quinoa saponin compositions and methods of use
|
US5597807A
(en)
*
|
1994-08-01 |
1997-01-28 |
University Of Saskatchewan |
Quinoa saponin compositions and methods of use
|
US6080408A
(en)
|
1994-08-22 |
2000-06-27 |
Connaught Laboratories Limited |
Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
US20010053365A1
(en)
*
|
1995-04-25 |
2001-12-20 |
Smithkline Beecham Biologicals S.A. |
Vaccines
|
US5820869A
(en)
*
|
1995-06-07 |
1998-10-13 |
American Home Products Corporation |
Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
|
US6300118B1
(en)
|
1995-06-07 |
2001-10-09 |
American Home Products Corporation |
Plasmids comprising a genetically altered feline immunodeficiency virus genome
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6231859B1
(en)
*
|
1996-12-02 |
2001-05-15 |
Aquila Biopharmaceuticals, Inc. |
Saponin adjuvant compositions
|
AUPO517897A0
(en)
|
1997-02-19 |
1997-04-11 |
Csl Limited |
Chelating immunostimulating complexes
|
JP4583511B2
(en)
*
|
1997-05-20 |
2010-11-17 |
ガレニカ ファーマシューティカルズ, インコーポレイテッド |
Triterpene saponin analogs with adjuvant and immunostimulatory activity
|
US6080725A
(en)
*
|
1997-05-20 |
2000-06-27 |
Galenica Pharmaceuticals, Inc. |
Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
|
WO1998056415A1
(en)
*
|
1997-06-11 |
1998-12-17 |
Aquila Biopharmaceuticals, Inc. |
Purified saponins as oral adjuvants
|
ES2500490T3
(en)
*
|
1997-08-29 |
2014-09-30 |
Antigenics Inc. |
Compositions comprising adjuvant QS-21 and polysorbate or cyclodextrin as excipient
|
WO1999017783A1
(en)
*
|
1997-10-03 |
1999-04-15 |
Galenica Pharmaceuticals, Inc. |
Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
AU760669B2
(en)
|
1998-04-28 |
2003-05-22 |
Galenica Pharmaceuticals, Inc. |
Polysaccharide-antigen conjugates
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US7049302B1
(en)
|
1998-08-10 |
2006-05-23 |
Antigenics Inc. |
Compositions of CPG and saponin adjuvants and uses thereof
|
US20010034330A1
(en)
*
|
1998-08-10 |
2001-10-25 |
Charlotte Kensil |
Innate immunity-stimulating compositions of CpG and saponin and methods thereof
|
US6262029B1
(en)
|
1998-08-14 |
2001-07-17 |
Galenica Pharmaceuticals, Inc. |
Chemically modified saponins and the use thereof as adjuvants
|
TW586935B
(en)
*
|
1998-09-14 |
2004-05-11 |
Kitasato Inst |
Saponin-containing vaccine preparation
|
ATE464907T1
(en)
|
1999-02-17 |
2010-05-15 |
Csl Ltd |
IMMUNOGENIC COMPLEXES AND METHODS RELATING THEM
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
US20040146521A1
(en)
*
|
1999-06-01 |
2004-07-29 |
Schenk Dale B. |
Prevention and treatment of synucleinopathic disease
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
AU7085400A
(en)
*
|
1999-09-02 |
2001-03-26 |
Antigenics, Inc. |
Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
|
WO2001024820A1
(en)
*
|
1999-10-07 |
2001-04-12 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
NZ518999A
(en)
*
|
1999-11-19 |
2002-12-20 |
Csl Ltd |
Vaccine compositions
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
AU5697001A
(en)
|
2000-03-31 |
2001-10-15 |
Purdue Research Foundation |
Method of treatment using ligand-immunogen conjugates
|
ES2374620T3
(en)
*
|
2000-06-20 |
2012-02-20 |
Corixa Corporation |
ANTIGEN MTB32A OF MYCOBACTERIUM TUBERCULOSIS WITH THE ACTIVE ACTIVE SITE AND FUSION PROTEINS OF THEMSELVES.
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
TWI255272B
(en)
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
NZ529347A
(en)
|
2001-04-04 |
2008-01-31 |
Nordic Vaccine Technology As |
Use of at least one sterol capable of interacting with a nucleic acid and at least saponin to form immunostimulating complexes ( IMSCO )
|
HUP0401127A3
(en)
*
|
2001-05-02 |
2006-03-28 |
Purdue Research Foundation |
Treatment and diagnosis of macrophage disease
|
DE60234782D1
(en)
*
|
2001-09-28 |
2010-01-28 |
Purdue Research Foundation |
TREATMENT PROCEDURE WITH LIGAND IMMUNOGENIC CONJUGATES
|
WO2003055514A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Antigenics Inc. |
Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
|
AU2003213118A1
(en)
*
|
2002-02-15 |
2003-09-09 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
SE0202110D0
(en)
*
|
2002-07-05 |
2002-07-05 |
Isconova Ab |
Iscom preparation and use thereof
|
US20080014194A1
(en)
*
|
2003-10-31 |
2008-01-17 |
Elan Pharmaceuticals, Inc. |
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
|
TW200509968A
(en)
*
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
US8506959B2
(en)
*
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US8697082B2
(en)
*
|
2002-11-01 |
2014-04-15 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US9034337B2
(en)
|
2003-10-31 |
2015-05-19 |
Prothena Biosciences Limited |
Treatment and delay of outset of synucleinopathic and amyloidogenic disease
|
US20040213808A1
(en)
*
|
2002-12-11 |
2004-10-28 |
Michael Lieberman |
Recombinant vaccine against flavivirus infection
|
US20050287170A1
(en)
*
|
2002-12-11 |
2005-12-29 |
Hawaii Biotech, Inc. |
Subunit vaccine against West Nile viral infection
|
US7262027B2
(en)
*
|
2003-03-14 |
2007-08-28 |
Medical College Of Ohio |
Polypeptide and DNA immunization against Coccidioides spp. infections
|
US20040242502A1
(en)
*
|
2003-04-08 |
2004-12-02 |
Galenica Pharmaceuticals, Inc. |
Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
EP1670507A4
(en)
*
|
2003-09-12 |
2007-10-17 |
Antigenics Inc |
Vaccine for treatment and prevention of herpes simplex virus infection
|
WO2005047860A2
(en)
|
2003-11-08 |
2005-05-26 |
Elan Pharmaceuticals, Inc. |
Antibodies to alpha-synuclein
|
ES2396555T3
(en)
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Antibodies that recognize beta amyloid peptide
|
PE20061329A1
(en)
|
2004-12-15 |
2006-12-08 |
Neuralab Ltd |
HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
|
US8168164B2
(en)
*
|
2006-02-03 |
2012-05-01 |
Purdue Research Foundation |
Targeted conjugates and radiation
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
WO2008094183A2
(en)
*
|
2006-07-11 |
2008-08-07 |
University Of Connecticut |
Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
US8147833B2
(en)
*
|
2007-02-23 |
2012-04-03 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
PL2583978T3
(en)
*
|
2007-02-23 |
2016-07-29 |
Prothena Biosciences Ltd Co |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
US20100172937A1
(en)
*
|
2007-05-03 |
2010-07-08 |
Kotwal Girish J |
Enveloped virus neutralizing compounds
|
ES2498040T3
(en)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases with humanized anti-beta antibodies
|
JO3076B1
(en)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
Immunotherapy regimes dependent on apoe status
|
CA2705808A1
(en)
*
|
2007-11-15 |
2009-05-22 |
Endocyte, Inc. |
Method of administering conjugates
|
EP2280987B1
(en)
|
2008-04-08 |
2018-05-23 |
Sloan-Kettering Institute for Cancer Research |
Triterpene saponins, methods of synthesis, and uses thereof
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
CN101791410B
(en)
*
|
2010-01-25 |
2013-03-27 |
中国药科大学 |
Preparation and application of conjugate of anti-infective medicament and polysaccharide and medicinal composition thereof
|
MD4177C1
(en)
*
|
2011-01-14 |
2013-02-28 |
Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова |
Method for vaccination against hepatitis B of persons with immunodeficiency
|
AU2012308149A1
(en)
|
2011-09-12 |
2014-03-27 |
Sheena Mary Geraldine MCCORMACK |
Methods and compositions for raising an immune response to HIV
|
EP3618836A4
(en)
*
|
2017-04-25 |
2021-01-13 |
Adjuvance Technologies, Inc. |
Triterpene saponin analogues
|
EP3897735A1
(en)
*
|
2018-12-21 |
2021-10-27 |
Sapreme Technologies B.V. |
Biologically active cluster of molecules
|
US20220160879A1
(en)
*
|
2019-04-11 |
2022-05-26 |
Triterpenoid Therapeutics, Inc. |
Methods and compositions for irreversible enzvme inhibition
|
CA3146481A1
(en)
*
|
2019-07-25 |
2021-01-28 |
Sapreme Technologies B.V. |
Saponin derivatives with improved therapeutic window
|
EP4003425A2
(en)
|
2019-07-25 |
2022-06-01 |
Sapreme Technologies B.V. |
Bioactive saponin linked to a functional moiety
|
IL299359A
(en)
|
2020-06-24 |
2023-02-01 |
Sapreme Tech Bv |
Saponin derivatives for use in medicine
|
CA3188708A1
(en)
|
2020-08-07 |
2022-02-10 |
Access To Advanced Health Institute |
Purified saponins and chromatographic process for purification of same
|
WO2022055352A1
(en)
*
|
2020-09-10 |
2022-03-17 |
Sapreme Technologies B.V. |
Semicarbazone-based saponin conjugate
|
WO2022164316A1
(en)
*
|
2021-01-26 |
2022-08-04 |
Sapreme Technologies B.V. |
Semicarbazone-based saponin conjugate
|
WO2023038517A1
(en)
*
|
2021-09-09 |
2023-03-16 |
Sapreme Technologies B.V. |
Semicarbazone-based saponin conjugate
|
EP4190359A1
(en)
*
|
2021-12-03 |
2023-06-07 |
Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE |
Saponin-based adjuvants and vaccines
|